Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689
Source: Acta Haematologica - Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research
More News: Drugs & Pharmacology | Germany Health | Hematology | Nutrition | Study | Thrombocytopenia